The medication is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
Ketorolac tromethamine injection is indicated for the short-term management of moderately severe acute pain that requires analgesia at the opioid level.
The Rx Report finds that 76% of consumers have had at least one active prescription for themselves or those they care for, and 79% have visited a pharmacy in the past year.